C-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 447-454

  Hu, Fang ^a   Gartenhaus, Ronald B ^a   Zhao, Xianfeng F ^a   Fang, Hong Bin ^a   Minkove, Samuel ^a   Poss, Daniella E ^a   Rapoport, Aaron P ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Burkitts lymphoma; C Myc; E2F1; NHL; Non Hodgkins lymphoma; PBK; PDZ binding kinase; TOPK

Indexed keywords

MYC PROTEIN; PROTEIN PBK; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

E2F1 TRANSCRIPTION FACTOR; FLOW CYTOMETRY; HUMANS; LYMPHOMA, NON-HODGKIN; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; TISSUE ARRAY ANALYSIS;

EID: 84875380237     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.010     Document Type: Article

References (44)

1. Abe Y., Matsumoto S., Kito K., Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem 2000, 275:21525-21531.
2. Gaudet S., Branton D., Lue R.A. Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci USA 2000, 97:5167-5172.
3. Park J.H., Lin M.L., Nishidate T., Nakamura Y., Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006, 66:9186-9195.
4. Zykova T.A., Zhu F., Lu C., Higgins L., Tatsumi Y., Abe Y., et al. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin Cancer Res 2006, 12:6884-6893.
5. Zhu F., Zykova T.A., Kang B.S., Wang Z., Ebeling M.C., Abe Y., et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology 2007, 133:219-231.
6. Park J.H., Nishidate T., Nakamura Y., Katagiri T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci 2010, 101:403-411.
7. Fukukawa C., Ueda K., Nishidate T., Katagiri T., Nakamura Y. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer 2010, 49:861-872.
8. Li S., Zhu F., Zykova T., Kim M.O., Cho Y.Y., Bode A.M., et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway. J Biol Chem 2011, 286:29601-29609.
9. Zykova T.A., Zhu F., Vakorina T.I., Zhang J., Higgins L.A., Urusova D.V., et al. T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity. J Biol Chem 2010, 285:29138-29146.
10. Matsumoto S., Abe Y., Fujibuchi T., Takeuchi T., Kito K., Ueda N., et al. Characterization of a MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun 2004, 325:997-1004.
11. Fujibuchi T., Abe Y., Takeuchi T., Ueda N., Shigemoto K., Yamamoto H., et al. Expression and phosphorylation of TOPK during spermatogenesis. Dev Growth Differ 2005, 47:637-644.
12. Dougherty J.D., Garcia A.D., Nakano I., Livingstone M., Norris B., Polakiewicz R., et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci 2005, 25:10773-10785.
13. Simons-Evelyn M., Bailey-Dell K., Toretsky J.A., Ross D.D., Fenton R., Kalvakolanu D., et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis 2001, 27:825-829.
14. Nandi A., Tidwell M., Karp J., Rapoport A.P. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells Mol Dis 2004, 32:240-245.
15. Ryu B., Kim D.S., Deluca A.M., Alani R.M. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2007, 2:e594.
16. Zlobec I., Molinari F., Kovac M., Bihl M.P., Altermatt H.J., Diebold J., et al. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Br J Cancer 2010, 102:151-161.
17. Shiraishi T., Terada N., Zeng Y., Suyama T., Luo J., Trock B., et al. Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 2011, 9:153.
18. Albino D., Scaruffi P., Moretti S., Coco S., Truini M., Di Cristofano C., et al. Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. Cancer 2008, 113:1412-1422.
19. Wuttig D., Baier B., Fuessel S., Meinhardt M., Herr A., Hoefling C., et al. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer 2009, 125(2):474-482.
20. Nandi A.K., Ford T., Fleksher D., Neuman B., Rapoport A.P. Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53. Biochem Biophys Res Commun 2007, 358:181-188.
21. Hu F., Gartenhaus R.B., Eichberg D., Liu Z., Fang H.B., Rapoport A.P. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene 2010, 29:5464-5474.
22. Nandi A.K., Rapoport A.P. Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF. Leuk Res 2006, 30:437-447.
23. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res 1986, 47:189-234.
24. Marcu K.B., Bossone S.A., Patel A.J. myc function and regulation. Annu Rev Biochem 1992, 61:809-860.
25. Sanchez-Beato M., Sanchez-Aguilera A., Piris M.A. Cell cycle deregulation in B-cell lymphomas. Blood 2003, 101:1220-1235.
26. Smith D.P., Bath M.L., Metcalf D., Harris A.W., Cory S. MYC levels govern hematopoietic tumor type and latency in transgenic mice. Blood 2006, 108:653-661.
27. Fan J., Zeller K., Chen Y.C., Watkins T., Barnes K.C., Becker K.G., et al. Time-dependent c-Myc transactomes mapped by array-based nuclear run-on reveal transcriptional modules in human B cells. PLoS One 2010, 5(3):e9691.
28. Cress W.D., Nevins J.R. A role for a bent DNA structure in E2F-mediated transcription activation. Mol Cell Biol 1996, 16:2119-2127.
29. Huang M.J., Cheng Y.C., Liu C.R., Lin S., Liu H.E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006, 34(11):1480-1489.
30. Rimsza L.M., LeBlanc M.L., Unger J.M., Miller T.P., Grogan T.M., Persky D.O., et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008, 112:3425-3433.
31. Klapper W., Stoecklein H., Zeynalova S., Ott G., Kosari F., Rosenwald A., et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008, 22:2226-2229.
32. Schrader A., Bentink S., Spang R., Lenze D., Hummel M., Kuo M., et al. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer 2012, 131:E348-E361.
33. Johnson N.A., Savage K.J., Ludkovski O., Ben-Neriah S., Woods R., Steidl C., et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009, 114:2273-2279.
34. Klapproth K., Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010, 149:484-497.
35. He L., He X., Lowe S.W., Hannon G.J. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007, 7:819-822.
36. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008, 40:43-50.
37. Chang T.C., Zeitels L.R., Hwang H.W., Chivukula R.R., Wentzel E.A., Dews M., et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci USA 2009, 106:3384-3389.
38. Sotillo E., Laver T., Mellert H., Schelter J.M., Cleary M.A., McMahon S., et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011, 30:2587-2594.
39. Odvody J., Vincent T., Arrate M.P., Grieb B., Wang S., Garriga J., et al. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene 2010, 29:3287-3296.
40. Molina-Privado I., Rodriguez-Martinez M., Rebollo P., Martin-Pérez D., Artiga M.J., Menárguez J., et al. E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Res 2009, 69:4052-4058.
41. Guo J., Parise R.A., Joseph E., Egorin M.J., Lazo J.S., Prochownik E.V., et al. Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 2009, 63:615-625.
42. Zeller K.I., Zhao X., Lee C.W., Chiu K.P., Yao F., Yustein J.T., et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 2006, 103:17834-17839.
43. Dougherty J.D., Garcia A.D.R., Nakano I., Livingstone M., Norris B., Polakiewicz R., et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci 2005, 25:10773-10785.
44. Park J.-H., Lin M.-L., Nishidate T., Nakamura Y., Katagiri T. PDZ-binding kinase/T-LAK cell originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006, 66:9186-9195.